EXAS - NASDAQ

Exact Sciences Corporation

EXAS·NASDAQ

$104.91

+0.0000%

HealthcareMedical - Diagnostics & Research

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$20.03B

EPS-1.1000

P/E Ratio-95.37

Earnings Date04/29/2026

5.86B

Assets

-1%

3Y-6.0%

5Y+19.0%

10Y+1454.0%

3.46B

Total Liabilities

-2%

3Y+9.0%

5Y+29.0%

10Y+8187.0%

2.40B

Total Equity

3Y-21.0%

5Y+7.0%

10Y+616.0%

Exact Sciences Corporation Funding & Solvency Profile

EXAS · NASDAQ

Current Assets

Cash & Cash Equivalents956.00M

Net Receivables298.65M

Inventory166.20M

Other Current Assets126.28M

Total Current Assets2 B

Non-Current Assets

Property, Plant & Equipment831.00M

Goodwill & Intangible Assets3.29B

Long-Term Investments0.00

Other Non-Current Assets185.81M

Total Non-Current Assets1 B

Total Assets

5.86B

Financial Health Analysis

Current Ratio

2.43x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.44x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

915 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

27% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Exact Sciences Corporation Balance Sheet

EXAS • NASDAQ

Exact Sciences Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	956M	600.9M	605.4M	242.5M	315.5M	1.5B	177.3M	160.4M	77.5M	48.9M	41.1M	58.1M	12.9M	13.3M	35.8M	78.8M	21.9M	4.9M	4.5M	4.8M
Short-Term Investments	8.7M	437.1M	172.3M	389.6M	715M	348.7M	146.4M	963.8M	347.2M	262.2M	265.7M	224.6M	120.4M	94.8M	57.6M	16.7M	2.4M	0.0	8.1M	16.2M
Cash & Short-Term Investments	964.7M	1B	777.6M	632.1M	1B	1.8B	323.7M	1.1B	424.7M	311.1M	306.9M	282.8M	133.3M	108.1M	93.4M	95.4M	24.3M	4.9M	12.6M	21.1M
Net Receivables	298.7M	249M	203.6M	158M	216.6M	233.2M	130.4M	45.3M	26.4M	8.5M	4.9M	1.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	298.7M	249M	203.6M	158M	216.6M	233.2M	130.4M	45.3M	26.4M	8.5M	4.9M	1.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	166.2M	162.4M	127.5M	118.3M	105M	92.3M	61.7M	39.1M	26M	6.8M	6.7M	4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	74.1M	33.2M	38.2M	19.4M	10.1M	7.1M	7.4M	3.5M	2.2M	593K	1M	246K	484K	190K	275K	386K
Other Current Assets	126.3M	122M	85.6M	73.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	500K	0.0	0.0	0.0
Total Current Assets	1.6B	1.6B	1.2B	982.3M	1.4B	2.2B	553.9M	1.2B	487.2M	333.6M	325.9M	291.7M	135.5M	108.7M	94.4M	95.7M	25.3M	5.1M	12.9M	21.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	831M	810.6M	842.1M	851.8M	754.5M	577.9M	581.8M	245.3M	80M	38.1M	34.1M	19.9M	11.2M	3.4M	2.6M	854K	458K	76K	601K	844K
Goodwill	2.4B	2.4B	2.4B	2.3B	2.3B	1.2B	1.2B	17.3M	2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	919.9M	1B	1.9B	2B	2.1B	847.1M	1.1B	29M	22.2M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	95K	432K	763K
Goodwill & Intangible Assets	3.3B	3.4B	4.3B	4.3B	4.4B	2.1B	2.3B	46.3M	24.2M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	95K	432K	763K
Other Non-Current Assets	185.8M	169.7M	177.4M	90.6M	74.6M	63.8M	23.3M	4.4M	7.2M	3.8M	4.1M	1.2M	0.0	0.0	0.0	0.0	0.0	600K	700K	800K
Total Non-Current Assets	4.3B	4.4B	5.3B	5.2B	5.3B	2.7B	3B	296M	111.3M	43.5M	38.2M	19.9M	11.2M	3.4M	2.6M	854K	458K	771K	1.7M	2.4M
Total Assets	5.9B	5.9B	6.5B	6.2B	6.7B	4.9B	3.5B	1.5B	598.6M	377M	364.3M	311.6M	146.6M	112.1M	97M	96.5M	25.8M	5.9M	14.6M	23.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	175.9M	89.6M	78.8M	74.9M	67.8M	35.7M	26M	28.1M	17.8M	710K	3.3M	2.6M	761K	3.7M	765K	1M	155K	683K	245K	158K
Accounts Payable	175.9M	89.6M	78.8M	74.9M	67.8M	35.7M	26M	28.1M	16.1M	710K	3.3M	2.6M	761K	3.7M	765K	1M	155K	683K	245K	158K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	276.7M	142.4M	94.1M	98M	215M	109M	98.2M	63.5M	22.7M	11.4M	13.5M	8M	2.8M	1.3M	1M	2M	1.4M	1.5M	2.8M	1.8M
Short Term Debt	39.3M	249.2M	50M	0.0	0.0	314M	834K	8K	182K	174K	166K	360K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	27.4M	29.4M	28.4M	19.7M	11.5M	7.9M	0.0	0.0	0.0	0.0	914K	891K	333K	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	2.2M	2.4M	527K	127K	309K	261K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1M	4.1M	5M	0.0	0.0	0.0
Other Current Liabilities	149.3M	223.7M	262.4M	211.5M	214.5M	162.9M	103.6M	44.5M	29.1M	18.3M	9.5M	5.3M	3.1M	6.1M	2M	0.0	0.0	2.9M	2.6M	4.4M
Total Current Liabilities	641.2M	732.2M	514.7M	412.7M	517.1M	633.1M	236.5M	136.6M	68.1M	30.7M	26.7M	17.5M	7.8M	11.5M	8M	7.2M	6.5M	5M	4.4M	6.4M
NON-CURRENT LIABILITIES
Long Term Debt	2.3B	2.3B	2.3B	2.2B	2.2B	1.9B	827.6M	689.2M	4.3M	4.6M	4.8M	1M	1M	1M	1M	1M	1M	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4M	8.6M	11.2M	0.0	0.0	0.0
Other Non-Current Liabilities	329.3M	315.5M	336M	352.5M	417.8M	51.3M	34.9M	17.7M	5.7M	5.7M	4.6M	3.7M	84K	358K	42K	21K	1K	3.3M	2.7M	2.5M
Total Non-Current Liabilities	2.8B	2.8B	2.8B	2.8B	2.8B	2.1B	981.2M	706.9M	10M	11.1M	10.5M	6.3M	3.6M	2.1M	5.5M	9.6M	13.2M	3.3M	2.7M	2.5M
Capital Lease Obligations	168.3M	184.5M	190.4M	210.8M	201.9M	132.6M	118.7M	8.2M	116K	686K	1.1M	360K	360K	711K	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	3.5B	3.5B	3.3B	3.2B	3.3B	2.7B	1.2B	843.1M	78.1M	41.7M	37.4M	22.6M	11.3M	13.5M	13.5M	16.8M	19.7M	8.3M	8.3M	8.9M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-97K	-97K	-97K
Common Stock	1.9M	1.9M	1.8M	1.8M	1.7M	1.6M	1.5M	1.2M	1.2M	1.1M	968K	887K	711K	639K	566K	522K	355K	275K	273K	269K
Additional Paid-In Capital	7.1B	6.9B	6.6B	6.3B	6B	4.3B	3.4B	1.7B	1.4B	1.1B	904.9M	709M	455.2M	372.1M	304.8M	272.4M	187.3M	169.9M	168.8M	165.5M
Retained Earnings	-4.7B	-4.5B	-3.5B	-3.3B	-2.6B	-2B	-1.1B	-1B	-860.6M	-745.8M	-578.6M	-420.8M	-320.8M	-274.2M	-221.8M	-193.1M	-181.6M	-172.5M	-162.7M	-150.8M
Accumulated Other Comprehensive Income/Loss	2.4M	-944K	1.4M	-5.2M	-1.4M	526K	-100K	-1.4M	-750K	-418K	-433K	-115K	125K	78K	-14K	1K	-1K	0.0	23K	6K
Total Stockholders' Equity	2.4B	2.4B	3.1B	3B	3.4B	2.2B	2.3B	680.9M	520.4M	335.3M	326.9M	289M	135.3M	98.6M	83.5M	79.8M	6.1M	-2.4M	6.3M	15M
Total Equity	2.4B	2.4B	3.1B	3B	3.4B	2.2B	2.3B	680.9M	520.4M	335.3M	326.9M	289M	135.3M	98.6M	83.5M	79.8M	6.1M	-2.4M	6.3M	15M
SUMMARY
Total Liabilities & Equity	5.9B	5.9B	6.5B	6.2B	6.7B	4.9B	3.5B	1.5B	598.6M	377M	364.3M	311.6M	146.6M	112.1M	97M	96.5M	25.8M	5.9M	14.6M	23.9M
Total Investments	8.7M	437.1M	172.3M	389.6M	715M	348.7M	146.4M	963.8M	347.2M	262.2M	265.7M	224.6M	120.4M	94.8M	57.6M	16.7M	2.4M	0.0	8.1M	16.2M
Total Debt	2.5B	2.8B	2.6B	2.4B	2.4B	2.3B	955M	689.3M	4.5M	5.5M	6M	3.9M	4.4M	2M	1M	1M	2M	0.0	0.0	0.0
Net Debt	1.6B	2.2B	1.9B	2.2B	2.1B	839.3M	777.8M	528.8M	-73M	-43.4M	-35.1M	-54.2M	-8.5M	-11.3M	-34.8M	-77.8M	-19.9M	-4.9M	-4.5M	-4.8M
Shares Outstanding	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298	189,471,298

SEC Filings

EXAS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	March 23, 2026	March 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 20, 2026	March 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 20, 2026	February 20, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 13, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 13, 2026	February 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 10, 2026	February 10, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 29, 2025	December 23, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 20, 2025	November 19, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 03, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing

Showing 1 to 10 of 471 filings

Related Guides

Blog Categories

Continue your EXAS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.